In the past year alone, rent prices have increased by 2.2 percent in Griefswald and 9.8 percent in Berlin. “More needs to be built, but this alone can’t stop the quickly growing prices of big cities,” said study director Michael Voigtländer. Students in Munich pay the most, an average of €600 per month, followed by Frankfurt am Main at €488 a month. The most affordable flats are in the eastern German city of Magdeburg, with prices set at €200 per month. The best priced university cities, where students can still snag accommodation for under €300 per month, are Leipzig, Jena, Greifswald, Kiel, Göttingen und Aachen. SEE ALSO: Weekend wanderlust: A walk through the Nobel trail of Göttingen The study includes an interactive map of Germany in which showcases how much flats 20 to 40 square meters costs based on if they are furnished or not, and how far they are located from an university. The study is based on data from the … [Read more...] about Student housing prices in Germany increasing up to 70 percent: study
Cost based pricing example
David Herzberg was alarmed when he heard that Richard Sackler, former chairman of opioid giant Purdue Pharma, was listed as an inventor on a new patent for an opioid addiction treatment. Patent No. 9861628 is for a fast-dissolving wafer containing buprenorphine, a generic drug that has been around since the 1970s. Herzberg, a historian who focuses on the opioid epidemic and the history of prescription drugs, said he fears the patent could keep prices high and make it more difficult for poor addicts to get treatment. “It’s hard not to have that reaction of, like … these vultures,” said Herzberg, an associate professor at the University of Buffalo. James Doyle, vice president and general counsel of Rhodes Pharmaceuticals, the Purdue subsidiary that holds the patent, said in an email statement that the company does not have a developed or approved product and “therefore no money has been made from this technology.” “The invention behind the … [Read more...] about Drugmakers Play The Patent Game To Lock In Prices, Block Competitors
Most products–especially commodities–are sold with a single price. You can buy an iPhone for largely the same price throughout the country. In the case of pharmaceuticals, however, there may be a case that prices should vary depending on their use. For instance, there may be a treatment which provides large benefits to patients with disease A and modest benefits to patients with disease B. A paper by Cole, Towse, Lorgelly, and Sullivan (2018) outlines three ways that drug prices could vary by indication to reflect differential value: a single drug authorised under different brand names with different prices; distinct “discounts” applied to different indications, and a single weighted average price. Types of differential pricing schemes Examples of how one could allow a drug’s price to vary by use include: Differential payment by approved indication (for example Trastuzumab for HER2+ breast cancer and gastric cancer) Differential … [Read more...] about The pros and cons of indication-specific pricing
President Donald Trump wants to control spending on drugs. One of his big ideas: include prices in advertisements, just like warnings about side effects. That’s not as simple as it sounds. Apart from legal questions about whether the Food and Drug Administration has the authority to require pricing in ads, other uncertainties arise. For example, what is the right number to use? There is a dizzying array of ways to look at drug prices, including average wholesale and average sales prices. And dosage factors in. Would the price be pegged to a monthly cost? A per-dose cost? Or, even more inscrutable, a “unit cost,” which may not equal a single dose? A final complication: The prices likely would not be what most consumers actually pay. Most patients with insurance typically shell out either a flat-dollar copayment or a percentage of the drug’s cost. Some patients get coupons that can reduce their cost to zero. An FDA working group is currently studying these … [Read more...] about Price Check On Drug Ads: Would Revealing Costs Help Patients Control Spending?
Since Kristen Catton started taking the drug Gilenya two years ago, she’s had only one minor relapse of her multiple sclerosis, following a bout of the flu. She can walk comfortably, see clearly and work part time as a nurse case manager at a hospital near her home in Columbus, Ohio. This is a big step forward; two drugs she previously tried failed to control her physical symptoms or prevent repeated flare-ups. This year, Catton, 48, got a shock. Her health insurance plan changed the way it handles the payments that the drugmaker Novartis makes to help cover her prescription’s cost. Her copayment is roughly $3,800 a month, but Novartis helps reduce that out-of-pocket expense with payments to the health plan. The prescription costs about $90,000 a year. Those Novartis payments no longer counted toward her family plan’s $8,800 annual pharmacy deductible. That meant once she hit the drugmaker’s payment cap for the copay assistance in April, she would have to pay … [Read more...] about Benefit Change Could Raise Costs For Patients Getting Drug Copay Assistance